Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

sacituzumab govitecan

sacituzumab govitecan
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Trodelvy POWDER FOR INJECTION, INTRAVENOUS 180 mg      
Comments:

Restricted to oncology in the outpatient setting. Reimbursement and insurance certification or PAP eligibility required prior to initiation of therapy.

Reviewed: Nov. 2021 (Trodelvy)

Last updated: Feb. 21, 2026
Rhazdrugs sacituzumab govitecan






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved